Senol, KazimFerhatoglu, Murat FerhatKocaeli, Aysen AkkurtDundar, Halit ZiyaKaya, Ekrem2024-05-252024-05-25202152168-023X2168-024810.1089/bari.2020.01102-s2.0-85102919039https://doi.org/10.1089/bari.2020.0110https://hdl.handle.net/20.500.14517/1651Akkurt Kocaeli, Aysen/0000-0001-7604-0605;Objective: To prospectively evaluate the postoperative morbidity, mortality, and weight loss evolution of patients who underwent a bariatric procedure during 1 year of follow-up. Methods: Since July 2016, a total of 101 patients' data have been prospectively registered in a database. Comorbidities, operating time, hospital stay, early and late complications rate, and weight loss evolution after 1 year of follow-up were recorded. Results: The mean age was 38.41 +/- 11.05 years with a mean body mass index (BMI) of 49.02 +/- 5.89 kg/m(2) (range 38-67). Laparoscopic sleeve gastrectomy (LSG) was performed in 93 patients (92.07%) and Roux-en-Y gastric bypass (RNYGB) in 8 patients (7.92%). Thirty-day morbidity rate was 7.92% (8/101). Within a mean 9.32 +/- 2.25 (range 1-19) months follow-up time, mean percent of the excess of weight loss of 1st, 6th, and 12th months were 22.7 +/- 6.1, 67.2 +/- 11.2, and 81.4 +/- 10.5, respectively. Diabetes (n = 38, 37.6%), hypertension (n = 13, 12.9%), and obstructive sleep apnea (n = 5, 4.9%) were resolved in 76%, 68.4%, and 100% of the patients, respectively (p < 0.001). Conclusions: LSG and RNYGB are safe and highly effective, particularly in patients with a BMI >50 kg/m(2). Both techniques have been presented with better clinical outcomes regarding significant comorbidity resolution in the early evolution of weight loss.eninfo:eu-repo/semantics/openAccessobesityrural surgerycomorbidity resolutionArticleQ4Q41616167WOS:00062972800001133763312